iVEAcare is a technology company.
iVEAcare has raised $28.0M across 1 funding round.
iVEAcare has raised $28.0M in total across 1 funding round.
iVEAcare is a development-stage medical device company specializing in neuromodulation therapy devices to address unmet clinical needs in chronic diseases, particularly targeting large patient populations like those with seizures.[1][2][3] Founded in 2023 and headquartered in Roseville, Minnesota, it emerged from stealth in April 2024 with a $27.5 million Series A funding round led by Vensana Capital, alongside Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner, reaching Series A stage with strong early momentum.[1][2][3] The company serves patients and clinicians in neurology, focusing on innovative therapies that improve outcomes through neuromodulation technology, including an AI-based approach for seizure management as indicated by its first patent filing in September 2024.[1][4]
iVEAcare originated as the third spin-off from NuXcel, a medical device accelerator managed by Mudit K. Jain, PhD, and Lynn Elliott, and backed by Treo Ventures.[2][3] Founded in 2023, it leverages expertise from medtech veterans; co-founder and Chairman Mudit Jain highlighted the spin-off's appeal to top investors, while Todd Kerkow was appointed President and CEO in April 2024.[2][3] Kerkow brings nearly three decades of experience from Guidant, Cameron Health (where he led development of the first subcutaneous implantable defibrillator, acquired by Boston Scientific for over $500M), Boston Scientific, and Cardionomic.[2] The idea emerged from NuXcel's focus on accelerating neuromodulation innovations, with early traction marked by the Series A close upon exiting stealth, enabling development of novel therapies.[2][3]
iVEAcare rides the neuromodulation wave in medtech, amplified by AI advancements for precision neurology treatments like epilepsy, where current options fall short for millions.[1][2][4] Timing aligns with surging investor interest—its Series A reflects confidence in AI-driven devices amid a post-2024 boom in neurotech, fueled by patent activity and regulatory tailwinds for minimally invasive implants.[3][4] Market forces favor it: aging populations drive chronic disease prevalence, while AI enhances seizure detection/prediction, positioning iVEAcare to disrupt a $10B+ neuromodulation market dominated by incumbents like Medtronic and NeuroPace.[1] As a NuXcel spin-out, it influences the ecosystem by validating accelerators as hubs for high-impact medtech, drawing talent and capital to Minnesota's growing device cluster.[2][3]
iVEAcare's near-term path centers on advancing its AI seizure therapy through clinical trials, leveraging $27.5M to hit milestones like FDA submissions by 2026-2027, with potential expansion to other chronic indications.[1][4] Trends like AI-medtech convergence and wearable neuromodulation will accelerate its trajectory, especially as data from real-world implants refines algorithms. Its influence could grow via partnerships with strategics (hinted in funding) or acquisitions, mirroring Cameron Health's path, solidifying iVEAcare as a neuromodulation frontrunner from its strong Series A launch.[2][3]
iVEAcare has raised $28.0M in total across 1 funding round.
iVEAcare's investors include HealthX Ventures, Vensana Capital.
iVEAcare has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $28.0M Series A | HealthX Ventures, Vensana Capital |